---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-091315"
form_type: "8-K"
ticker: "CTSO"
cik: "0001175151"
company_name: "Cytosorbents Corp"
filed_at: "2024-08-20T23:59:59+00:00"
generated_at: "2026-05-31T08:24:47.273725+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# CytoSorbents amends royalty agreement with ROKK, redefines gross revenue scope

## Summary
- Royalty rate remains 3% of gross revenues from CytoSorb sales under amended agreement.
- Amended and Restated Agreement clarifies definitions of 'gross revenue' with specified deductions.
- Covered Products now explicitly include CytoSorb, VetResQ, ECOS-300CY, and certain DrugSorb versions.
- Agreement dated August 16, 2024, amends the original 2003 Letter Agreement with ROKK.

## SEC filing metadata
- accession: 0001104659-24-091315
- form_type: 8-K
- ticker: CTSO
- cik: 0001175151
- company_name: Cytosorbents Corp
- filed_at: 2024-08-20T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1175151/000110465924091315/0001104659-24-091315-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1175151/000110465924091315/tm2422183-1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-091315
- JSON: https://secwatch.observer/filing/0001104659-24-091315.json
- Plain text: https://secwatch.observer/filing/0001104659-24-091315.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.